The Alzheimer’s Association reports that an extremely large cost savings for the current U.S. population can be realized from early diagnosis of Alzheimer's.
The majority of the people diagnosed with AD can be subjected to invasive and costly procedures.
Additionally, they get a subjective clinical diagnosis without the confirmation of a biomarker, like the DISCERN™ test provides.